Why the study?
Does interim PET/CT after one cycle of chemoimmunotherapy predict progression-free survival in patients with newly diagnosed DLBCL?
Population
112 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
Design
Cohort
Follow-up
2 years
Authors
Loading...
Interim PET/CT after one cycle cannot safely discriminate prognostic groups in DLBCL; leaves open its role for early risk stratification.
Does interim PET/CT after one cycle of chemoimmunotherapy predict progression-free survival in patients with newly diagnosed DLBCL?
Interim PET/CT after one cycle of chemoimmunotherapy is not able to safely discriminate PET-positive and PET-negative patients in different prognostic groups for DLBCL.
Mylam et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: